Follicular Lymphoma: Complete ICD-11 Coding Guide (2A80)
1. Introduction
Follicular lymphoma (FL) represents one of the most prevalent hematologic malignancies among mature B-cell non-Hodgkin lymphomas. It is an oncologic disease characterized by abnormal proliferation of B cells originating from the germinal center of lymphoid follicles, predominantly centrocytes and centroblasts. This condition presents a distinctive architectural pattern, generally with follicular growth that can be observed in histopathologic analyses of compromised lymphoid tissues.
The clinical importance of follicular lymphoma resides in its generally indolent nature, yet chronic and recurrent course. Although it frequently presents with slow progression, the disease has the potential for transformation to more aggressive forms, especially to diffuse large B-cell lymphoma. This dual characteristic – indolent behavior with risk of transformation – makes clinical management particularly challenging and requires prolonged and careful follow-up.
From an epidemiologic perspective, follicular lymphoma represents a significant proportion of lymphomas diagnosed annually in adult populations, being more common in middle-aged and elderly individuals. The disease affects the quality of life of patients and their families, demanding considerable resources from health systems for diagnosis, treatment, and follow-up.
Precise coding using ICD-11 is fundamental for multiple purposes: it enables appropriate epidemiologic tracking, facilitates comparative international studies, aids in health resource planning, ensures appropriate reimbursement in fee-for-service payment systems, and contributes to clinical research that depends on accurate population data. The transition from ICD-10 to ICD-11 brought greater specificity and clarity in the classification of this type of malignancy.
2. Correct ICD-11 Code
Code: 2A80
Description: Follicular lymphoma
Parent category: Neoplasms of mature B cells
Official definition: Follicular lymphoma (FL) is a neoplasm composed of B cells from the germinal center of the lymphoid follicle, usually centrocytes and centroblasts (transformed large cells), which present a pattern at least partially follicular. The characteristic genetic alteration is the t(14;18) translocation with BCL2 gene rearrangement, frequently observed in these cases.
A fundamental aspect of the definition is that if diffuse areas of any size composed predominantly or entirely of blastic cells are present in any case of follicular lymphoma, an additional diagnosis of diffuse large B-cell lymphoma should also be established. This situation represents a histological transformation that significantly alters the prognosis and therapeutic approach.
Additionally, the definition allows lymphomas composed of centrocytes and centroblasts with a completely diffuse pattern in the sampled tissue to be included in this category, provided that the cytological and immunophenotypic criteria are compatible with follicular lymphoma.
This classification belongs to the larger group of neoplasms of mature B cells, differentiating itself from other entities by its specific morphological, immunophenotypic, and molecular characteristics. Diagnostic accuracy requires integration of clinical, histopathological, immunohistochemical, and frequently molecular study data.
3. When to Use This Code
Code 2A80 should be applied in specific clinical situations where the diagnosis of follicular lymphoma has been established through well-defined criteria:
Scenario 1: Lymphadenopathy with histopathological confirmation of follicular pattern Patient presenting with enlargement of cervical, axillary, or inguinal lymph nodes, submitted to excisional biopsy demonstrating proliferation of germinal center B cells with follicular architectural pattern in at least part of the sample. Immunohistochemistry reveals positivity for CD10, BCL6, and characteristically BCL2 (due to genetic rearrangement). This is the classic scenario for use of code 2A80.
Scenario 2: Disease diagnosed at advanced stage Patient with involvement of multiple lymph node sites and bone marrow involvement, where lymph node biopsy demonstrates follicular lymphoma grade 1 or 2 (predominance of centrocytes over centroblasts). Even with disseminated disease, maintaining the follicular pattern without transformation, the appropriate code remains 2A80.
Scenario 3: Follicular lymphoma grade 3A Patient diagnosed with follicular lymphoma grade 3A, characterized by a higher proportion of centroblasts, but maintaining recognizable centrocytes and preserved follicular pattern. This subtype still falls under code 2A80, unlike grade 3B which is frequently treated as diffuse large B-cell lymphoma.
Scenario 4: Incidental finding on splenectomy Patient submitted to splenectomy for other reasons, with incidental histopathological finding of splenic infiltration by follicular lymphoma. Microscopic analysis reveals white pulp expanded by neoplastic follicles with germinal center B cells. This finding justifies coding as 2A80.
Scenario 5: Recurrence of previously treated follicular lymphoma Patient with history of follicular lymphoma treated with chemotherapy or immunotherapy, presenting with documented recurrence by biopsy that maintains follicular pattern without evidence of transformation to high-grade lymphoma. Coding continues to be 2A80 for recurrent disease.
Scenario 6: Follicular lymphoma with minor diffuse component Patient whose biopsy reveals predominance of follicular pattern (more than 75% of the sample) with small areas of diffuse growth, but without blastic cells in sufficient quantity to characterize transformation. In this case, code 2A80 is appropriate, without need for additional coding for diffuse large B-cell lymphoma.
4. When NOT to Use This Code
There are specific situations where code 2A80 should not be applied, and alternative codes must be used instead:
Exclusion by histological transformation: When biopsy demonstrates diffuse areas composed predominantly of blastic cells (centroblasts), configuring transformation to diffuse large B-cell lymphoma, it should be coded additionally as 2A81. In cases where transformation is complete and no follicular pattern is identifiable, only code 2A81 should be used.
Exclusion by cell type: If the lymphoid neoplasm is composed of T cells or mature NK cells, regardless of architectural pattern, the correct code belongs to a completely different category. These conditions require specific codes for T-cell and NK neoplasms.
Exclusion by leukemic presentation: When the mature B-cell neoplasm presents primarily with peripheral blood and bone marrow involvement, without significant lymph node mass and with leukemia characteristics (such as chronic lymphocytic leukemia), the appropriate code is 2A82 (Mature B-cell neoplasm with leukemic behavior).
Exclusion by plasmacytic differentiation: If the B-cell proliferation shows plasmacytic differentiation, as occurs in multiple myeloma, plasmacytoma, or other plasma cell neoplasms, the correct code is 2A83 (Plasma cell neoplasms), not 2A80.
Exclusion by other specific B-cell lymphoma subtypes: Mature B-cell lymphomas with specific characteristics that classify them in other categories – such as marginal zone lymphoma, lymphoplasmacytic lymphoma, Burkitt lymphoma – have their own codes within the mature B-cell neoplasm category and should not be coded as 2A80.
Exclusion by unconfirmed diagnosis: Reactive lymphadenopathy, follicular hyperplasia, or other benign conditions that may clinically mimic follicular lymphoma should not receive this code. Histopathological confirmation is mandatory.
5. Step-by-Step Coding Process
Step 1: Assess diagnostic criteria
The first fundamental step is to confirm that the diagnosis of follicular lymphoma has been properly established. This requires:
Histopathological evaluation: Excisional lymph node biopsy or biopsy of involved tissue demonstrating lymphoid proliferation with an architectural pattern that is at least partially follicular. Microscopic analysis must identify centrocytes and centroblasts in variable proportions.
Immunohistochemistry: Characteristic immunophenotypic profile showing B cells (CD20 positive) with germinal center markers (CD10 and/or BCL6 positive) and, typically, aberrant BCL2 expression (in contrast to reactive follicles which are BCL2 negative).
Molecular studies when available: Demonstration of t(14;18) translocation with BCL2 gene rearrangement through techniques such as FISH (fluorescence in situ hybridization) or PCR, although not all cases present this alteration.
Staging evaluation: Performance of complementary examinations including computed tomography or PET-CT to assess disease extent, bone marrow biopsy, and complete laboratory workup.
Step 2: Verify specifiers
After confirming the basic diagnosis, specific characteristics must be documented:
Histological grade: Determine the grade of follicular lymphoma (1, 2, 3A, or 3B) based on the count of centroblasts per high-power field. Grades 1-2 are considered low grade, grade 3A intermediate, and grade 3B often treated as high grade.
Disease extent: Document staging according to Ann Arbor classification (stages I to IV), considering the number of involved lymph node sites, presence of extranodal disease, and bone marrow involvement.
Prognostic index: Calculate the FLIPI (Follicular Lymphoma International Prognostic Index) when applicable, considering age, staging, hemoglobin levels, LDH levels, and number of involved lymph node areas.
Presence of transformation: Carefully assess whether areas of transformation to high-grade lymphoma exist, which requires additional coding.
Step 3: Differentiate from other codes
2A81 (Diffuse large B-cell lymphomas): The main difference lies in the architectural pattern and predominant cell type. While follicular lymphoma (2A80) presents a follicular pattern with centrocytes and centroblasts, diffuse large B-cell lymphoma presents a diffuse pattern with predominance of large blastic cells. If there is transformation of a follicular lymphoma to DLBCL, both codes may be necessary.
2A82 (Mature B-cell neoplasia with leukemic behavior): This category includes conditions such as chronic lymphocytic leukemia and prolymphocytic leukemia, which present primarily with peripheral blood and bone marrow involvement. Follicular lymphoma may involve bone marrow, but does not typically present as leukemia and maintains lymph node masses as the principal feature.
2A83 (Plasma cell neoplasms): These neoplasms show plasmacytic differentiation with monoclonal immunoglobulin production. Follicular lymphoma is composed of germinal center B cells without significant plasmacytic differentiation. Immunohistochemistry and morphology are clearly distinct.
Step 4: Required documentation
For appropriate coding, the medical record must contain:
Checklist of mandatory information:
- Complete anatomopathological report with detailed morphological description
- Immunohistochemistry panel with relevant markers
- Histological grade of follicular lymphoma
- Bone marrow biopsy result
- Imaging studies for staging
- Laboratory data including complete blood count, LDH, renal and hepatic function
- Clinical staging according to Ann Arbor
- Documentation of B symptoms if present
- Calculated prognostic indices
- Proposed therapeutic plan
Adequate documentation: The documentation must be clear regarding the diagnosis of follicular lymphoma, specifying grade, staging, and presence or absence of transformation, allowing coders to unequivocally identify code 2A80 as appropriate.
6. Complete Practical Example
Clinical Case:
A 58-year-old female patient sought medical care reporting progressive enlargement of cervical and axillary lymph nodes over six months, associated with fatigue and occasional night sweats. On physical examination, she presented with multiple bilateral cervical adenomegalies, the largest measuring approximately 3 cm, in addition to palpable axillary lymph nodes bilaterally. There was no hepatosplenomegaly.
Initial laboratory tests revealed hemoglobin of 11.2 g/dL, normal leukocytes, normal platelets, and slightly elevated LDH. An excisional biopsy of a cervical lymph node was performed.
Histopathological examination demonstrated lymph node architecture altered by lymphoid proliferation with a predominantly follicular pattern, composed of centrocytes and centroblasts. The count revealed 8 centroblasts per high-power field, characterizing grade 2. No diffuse areas with blastic cells were identified.
Immunohistochemistry showed: CD20 positive, CD10 positive, BCL6 positive, BCL2 strongly positive (aberrant), CD3 negative, CD5 negative, cyclin D1 negative, and Ki-67 of approximately 20%.
Molecular study by FISH confirmed the presence of t(14;18) translocation with BCL2 gene rearrangement.
Complementary staging included PET-CT which demonstrated multiple involved lymph node chains above and below the diaphragm (cervical, axillary, mediastinal, retroperitoneal, and inguinal), characterizing stage IV. Bone marrow biopsy revealed focal infiltration by follicular lymphoma in approximately 15% of the sample.
Step-by-Step Coding:
Criteria Analysis:
- Histopathological confirmation of grade 2 follicular lymphoma with predominantly follicular pattern
- Characteristic immunophenotype with germinal center B cells (CD10+, BCL6+) and aberrant BCL2 expression
- Molecular confirmation of t(14;18) translocation
- Absence of areas of transformation to diffuse large B-cell lymphoma
- Stage IV with bone marrow involvement
Code Selected: 2A80 - Follicular lymphoma
Complete Justification: The code 2A80 is appropriate because all diagnostic criteria for follicular lymphoma are present: proliferation of germinal center B cells (centrocytes and centroblasts) with follicular architectural pattern, characteristic immunophenotype, and molecular confirmation. Grade 2 still falls within the category of indolent follicular lymphoma. There is no evidence of transformation to high-grade lymphoma that would justify additional coding as 2A81. The presentation is not leukemic (excluding 2A82) and there is no plasmacytic differentiation (excluding 2A83).
Applicable Complementary Codes: Additional codes may be necessary to document complications such as anemia (if symptomatic), specific location of extranodal involvement if present, or adverse effects of treatment when initiated. Staging and grade should be documented in the medical record, although they may not have separate specific ICD-11 codes.
7. Related Codes and Differentiation
Within the Same Category:
2A81: Diffuse large B-cell lymphomas
When to use 2A81 vs. 2A80: Use 2A81 when lymphoid proliferation presents a diffuse architectural pattern (non-follicular) with predominance of large blastic cells (centroblasts or immunoblasts). In cases of follicular lymphoma with transformation, where diffuse areas composed predominantly of blastic cells are present, both codes may be necessary.
Main difference: The architectural pattern (follicular vs. diffuse) and the predominant cell type (mixture of centrocytes and centroblasts vs. large blastic cells) are the fundamental distinguishing characteristics.
2A82: Mature B-cell neoplasm with leukemic behavior
When to use 2A82 vs. 2A80: Code 2A82 is appropriate for B-cell neoplasms that present primarily with peripheral blood and bone marrow involvement, such as chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, or hairy cell leukemia. These conditions have clinical presentation and behavior distinct from follicular lymphoma.
Main difference: The primary clinical presentation (leukemic vs. lymph nodal) and the specific cytologic and immunophenotypic characteristics differentiate these entities.
2A83: Plasmacytic neoplasms
When to use 2A83 vs. 2A80: Use 2A83 for neoplasms showing plasmacytic differentiation, including multiple myeloma, solitary plasmacytoma, and other plasmacytic proliferations. These cells produce monoclonal immunoglobulins and have morphology and immunophenotype characteristic of plasmacytes.
Main difference: Cell differentiation (germinal center B cells vs. plasmacytes) and monoclonal protein production are distinguishing characteristics.
Differential Diagnoses:
Reactive follicular hyperplasia: Benign condition that may mimic follicular lymphoma clinically and even radiologically. Distinction requires biopsy showing polyclonal reactive follicles, BCL2 negative in germinal centers, and absence of BCL2 rearrangement.
Marginal zone lymphoma: May present with partially follicular pattern, but neoplastic cells are marginal zone B cells, not germinal center cells, with distinct immunophenotype (typically CD10 negative).
Mantle cell lymphoma: May be confused especially in cases with nodular pattern, but is characterized by small to medium cells with irregular nuclei, expression of CD5 and cyclin D1, and t(11;14) translocation.
8. Differences with ICD-10
Equivalent ICD-10 code: C82 - Follicular non-Hodgkin lymphoma
Main changes in ICD-11:
The transition from ICD-10 to ICD-11 brought significant refinements in the classification of follicular lymphoma. In ICD-10, code C82 included subdivisions based primarily on histologic grade and anatomic location (C82.0 to C82.9), with categories such as "follicular lymphoma of small cleaved cells," "mixed follicular lymphoma," and "follicular lymphoma of large cells."
ICD-11 simplifies this approach with the unified code 2A80, eliminating the need for multiple subcodes based on grade. The new classification emphasizes biological and molecular characteristics more than purely morphological ones, aligning better with the World Health Organization Classification for hematopoietic tumors.
Practical impact of these changes:
The simplification reduces confusion in coding, especially in cases where grading may be subjective or where there is histologic heterogeneity. Coders and healthcare professionals need to adapt to the single code 2A80, documenting grade and other characteristics in complementary fields of the electronic health record rather than through subcodes.
The change also facilitates epidemiological analyses and international comparative studies, as it reduces variability in coding between different institutions and countries. Health information systems needed to be updated to adequately map old ICD-10 codes to the new ICD-11 code, ensuring continuity in historical data series.
9. Frequently Asked Questions
1. How is a definitive diagnosis of follicular lymphoma made?
Definitive diagnosis requires tissue biopsy of involved tissue, preferably excisional biopsy of a lymph node. Histopathological analysis identifies the characteristic follicular pattern and cellular composition. Immunohistochemistry is essential to confirm the germinal center B-cell phenotype and aberrant BCL2 expression. Molecular studies demonstrating the t(14;18) translocation provide additional confirmation, although they are not mandatory if morphological and immunophenotypic findings are typical. Fine needle aspiration alone is insufficient for definitive diagnosis.
2. Is treatment available in public health systems?
Treatment for follicular lymphoma is generally available in public health systems in most countries, although the availability of specific therapies may vary. Therapeutic options include watchful waiting for asymptomatic low-volume disease, combination chemotherapy, immunotherapy with monoclonal antibodies, radiotherapy for localized disease, and newer targeted therapies. Specific coverage depends on local health policies and institutional protocols, but effective basic treatments are widely accessible.
3. How long does treatment last?
Treatment duration varies considerably depending on staging, histological grade, and therapeutic response. Patients with asymptomatic disease may be observed without immediate treatment for months or years. When indicated, chemotherapy typically involves 6 to 8 months of cycles. Maintenance therapy with monoclonal antibodies may extend for an additional 2 years. Follicular lymphoma is generally considered a chronic disease requiring prolonged follow-up, often for life, with the possibility of multiple lines of treatment over time due to relapses.
4. Can this code be used in medical certificates?
Yes, code 2A80 can and should be used in official medical documentation, including certificates when appropriate. However, the inclusion of diagnostic codes in certificates for patients varies according to local regulations and the purpose of the document. For work absence certificates, medical reports for insurers, or documentation for disability benefits, accurate coding is important. Some documents may require only textual description of the diagnosis, while others specifically request ICD codes. Always consider confidentiality issues and provide only information necessary for the specific purpose of the certificate.
5. What is the difference between follicular lymphoma and Hodgkin lymphoma?
They are completely distinct entities. Follicular lymphoma is a non-Hodgkin lymphoma of mature B cells characterized by proliferation of germinal center cells with a follicular pattern. Hodgkin lymphoma is characterized by the presence of Reed-Sternberg cells in a background of reactive inflammatory cells. They have different clinical presentations, treatments, and prognoses. Hodgkin lymphoma has completely separate ICD-11 codes and should not be confused with follicular lymphoma.
6. Can follicular lymphoma cure itself spontaneously?
Spontaneous regressions are extremely rare, but have been documented occasionally in the medical literature. However, spontaneous remission should not be expected as a typical course. Follicular lymphoma is generally a chronic disease that persists without treatment. Even with effective treatment, the disease frequently relapses, although there may be long periods of remission. The "watchful waiting" approach in selected cases does not mean expectation of spontaneous cure, but recognition that immediate treatment may not be necessary for asymptomatic low-volume disease.
7. How to differentiate follicular lymphoma from benign lymph node enlargement?
Clinically, it can be challenging, as both present with lymphadenopathy. Features suggesting lymphoma include: lymph nodes persistently enlarged for more than 4-6 weeks without apparent cause, absence of signs of infection, firm and painless lymph nodes, progressive growth, and presence of B symptoms (fever, night sweats, weight loss). However, definitive diagnosis always requires histopathological confirmation. Reactive lymphadenopathy shows polyclonal follicles with BCL2-negative germinal centers, while follicular lymphoma shows monoclonal BCL2-positive proliferation.
8. Can patients with follicular lymphoma work normally?
Many patients with follicular lymphoma maintain normal functional capacity, especially those with low-grade disease under observation or in remission after treatment. The ability to work depends on individual factors including disease staging, symptoms, treatment side effects, and type of occupation. During active chemotherapy treatment, there may be a need for temporary leave. During phases of stable disease or remission, many patients resume normal professional activities. Individualized assessments considering functional status, occupational demands, and medical recommendations are necessary to determine work capacity in each case.
Conclusion:
The ICD-11 code 2A80 for follicular lymphoma represents an essential tool for accurate documentation of this mature B-cell neoplasm. Appropriate coding requires clear understanding of diagnostic criteria, differentiation from other related entities, and complete documentation of clinical and pathological characteristics. Healthcare professionals, coders, and managers should familiarize themselves with the specificities of this code to ensure accuracy in medical records, facilitate clinical research, and optimize health resource planning. The transition from ICD-10 to ICD-11 simplified the coding approach, but maintains the need for detailed documentation of the individual characteristics of each case for appropriate clinical management.
External References
This article was prepared based on reliable scientific sources:
- 🌍 WHO ICD-11 - Follicular lymphoma
- 🔬 PubMed Research on Follicular lymphoma
- 🌍 WHO Health Topics
- 📊 Clinical Evidence: Follicular lymphoma
- 📋 Ministry of Health - Brazil
- 📊 Cochrane Systematic Reviews
References verified on 2026-02-04